중동 및 아프리카 근골격계(MSK) 질병 관리 시장 – 2030년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

중동 및 아프리카 근골격계(MSK) 질병 관리 시장 – 2030년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Nov 2022
  • MEA
  • 350 Pages
  • 테이블 수: 368
  • 그림 수: 60

Middle East And Africa Musculoskeletal Msk Disease Management Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2024 –2030
Diagram 시장 규모(기준 연도)
백만 달러
Diagram 시장 규모(예측 연도)
백만 달러
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

중동 및 아프리카 근골격계(MSK) 질환 관리 시장, 유형별(디지털 바이오피드백 시스템, 근골격계 중심 디지털 앱, 솔루션 등), 기술(정밀 모션 기술, 컴퓨터 비전 기술 및 기타 기술), 통합 유형(전화, 태블릿, 컴퓨터 및 기타), 모달리티(가상 치료, 대면 치료, 맞춤형/개인화 치료 및 기타), 애플리케이션(수술 전 애플리케이션 및 수술 후 애플리케이션), 환자 집단(소아과, 성인 및 노인과), 최종 사용자(병원 및 진료소, 요양원, 건강 센터, 재활 센터, 가상/재택 건강 관리 시설 및 기타) - 업계 동향 및 2030년까지의 예측.

근골격계(MSK) 질병 관리 시장

중동 및 아프리카 근골격계(MSK) 질병 관리 시장 분석 및 통찰력

MSK 질환 진단을 위한 기술 발전에 대한 수요 증가, MSK 질환에 대한 인식 제고, 류마티스 관절염(RA) 유병률 증가, 뼈 골절 사례 증가는 시장 성장을 촉진할 것으로 예상되는 요인입니다.

근골격계(MSK) 질병 관리 시장

근골격계(MSK) 질병 관리 시장

반면, 시장 주체들의 전략적 이니셔티브, 제품 개발, MSK 질병 관리에 있어서 원격진료의 활용, MSK 질병 관리를 위한 MDA와 가정 건강관리의 활용 증가는 시장 성장의 기회가 될 수 있습니다.

그러나 정형외과 질환의 진단 및 치료에 드는 비용이 높고 MSK 통증을 치료하는 데 사용되는 강력한 약물의 사용이 증가함에 따라 시장 성장이 제한될 것으로 예상됩니다.

약물 개발 및 설계에서 MSK 질병 관리 사용에 대한 수요 증가는 중동 및 아프리카의 시장 성장을 촉진할 것으로 예상됩니다. Data Bridge Market Research는 중동 및 아프리카 근골격계(MSK) 질병 관리 시장이 2023년에서 2030년까지의 예측 기간 동안 20.3%의 CAGR로 성장할 것이라고 분석합니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 해

2021 (2023-2030년까지 맞춤 설정 가능)

양적 단위

수익은 백만 달러, 가격은 미화로 표시됨

다루는 세그먼트

유형별(디지털 바이오피드백 시스템, 근골격계 중심 디지털 앱, 솔루션 및 기타), 기술별(정밀 모션 기술, 컴퓨터 비전 기술 및 기타 기술), 통합 유형별(전화, 태블릿, 컴퓨터 및 기타), 모달리티별(가상 치료, 대면 치료, 맞춤형/개인화된 치료 및 기타), 애플리케이션별(수술 전 애플리케이션 및 수술 후 애플리케이션), 환자 집단별(소아과, 성인 및 노인과), 최종 사용자별(병원 및 진료소, 요양원, 건강 센터, 재활 센터, 가상/홈 헬스케어 시설 및 기타)

적용 국가

남아프리카, 사우디아라비아, UAE, 이집트, 바레인, 쿠웨이트, 오만, 카타르, 이스라엘, 기타 중동 및 아프리카

시장 참여자 포함

RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc., Sword Health, Inc., SPRITE HEALTH 및 Limber Health, Inc. 등이 있습니다.

시장 정의

근골격계 질환(MSK) 또는 장애는 150개 이상의 다양한 질병 또는 상태로 구성되며, 이는 내부적으로 인체 시스템에 영향을 미치고 근육, 뼈, 관절 및 인접한 결합 조직의 결핍을 특징으로 하며, 이는 평생 기능과 참여에 장애를 초래합니다. 이러한 상태는 통증, 제한된 보행 운동 및 손재주를 특징으로 하며, 이로 인해 사람들의 일하고 사회에 참여하는 적성이 감소합니다.

MSK 질환 관리에는 디지털 바이오피드백 시스템(DBS), MDA 및 치료법을 사용하는 원격진료와 통합된 의사와의 상담이 포함됩니다. 신체 활동 및 체중 관리 프로그램도 관절염 환자에게 중요한 자기 관리 활동입니다 . 가상 치료 또는 원격 상담은 MSK 실무에서 화상 회의 및 전화 상담을 구현하는 전체론적 접근 방식을 수반합니다.

  • 가까운 미래에는 원격 의료와 가상 기술을 이해할 뿐만 아니라 MSK 질병 관리 도구와 이를 통해 제공되는 지식을 활용하여 가설을 개발하고 양질의 목표를 식별할 수 있는 사람들이 신체적 움직임과 수술 후 응용 프로그램을 통한 MSK 질병 관리와 관련된 중요한 결정을 내릴 것입니다.

중동 및 아프리카 근골격계(MSK) 질병 관리 시장 역학

운전자

  • 근골격계 질환 진단의 기술적 발전(MSDS)

근골격계(MSK) 질환은 근육, 인대, 신경, 힘줄, 연골 및 디스크와 같은 MSK 시스템에서 인체의 움직임에 영향을 미치는 부상 및 장애입니다. 일반적인 MSK 상태 중 일부는 중증 근무력증, 골관절염(OA), 통풍, RA, 허리 통증, 골다공증 및 전신성 홍반 루푸스(SLE)입니다. MSK 통증에는 다양한 원인이 있습니다. 예를 들어, 근육 조직은 일상 활동 중 마모로 인해 손상될 수 있습니다. 염좌, 교통사고, 낙상, 갑작스러운 움직임, 골절, 탈구 및 직접적인 근육 타격으로 인한 인체 부위의 부담도 MSK 통증을 유발합니다.

  • 뼈 골절 사례 증가

골절은 부러진 뼈에 대한 의학적 정의입니다. 골절은 일반적으로 낙상, 교통사고 또는 스포츠 부상과 같은 부상의 결과입니다. 그러나 특정 의학적 상태와 반복적인 힘(예: 달리기)은 특정 유형의 골절 위험을 증가시킬 수 있습니다. 뼈에 견딜 수 있는 것보다 더 많은 압력이 가해지면 금이 가거나 부러집니다. 모든 크기의 골절을 골절이라고 합니다. 골절이 피부를 뚫으면 개방 골절(복합 골절)이라고 합니다. 응력 골절은 뼈에 대한 반복적 또는 장기간의 힘으로 인해 발생하는 골절입니다. 반복적인 스트레스는 뼈를 약화시켜 결국 부러집니다.

기회

  • 근골격계 질환(MSK) 관리에 있어서 원격진료 활용

원격진료는 환자에게 비용 효율적이고 양질의 치료를 제공합니다. 사전 방문 계획을 통해 원격진료를 적절히 시행할 수 있으며, 환자와 의사에게 기능적인 원격진료 장비가 제공됩니다. MSK 질환을 치료하는 의사는 원격진료를 통해 체계적인 MSK 검사를 실시합니다. 일반적인 가정용품을 사용하면 의사가 직접 임상 검사 동작을 재현할 수 있습니다. 가정 간병 지침과 온라인 재활은 치료의 초기 관리를 제공합니다.

  • 주요 시장 참여자의 전략적 이니셔티브

근골격계(MSK) 질환의 증가는 전략적 사업 아이디어에 대한 필요성을 증가시킵니다. 여기에는 파트너십, 사업 확장, 협업 및 기타 개발이 포함됩니다. 중동 및 아프리카 근골격계(MSK) 질환 관리 시장에서 많은 건강 기관과 시장 참여자는 고객에게 투자 수익을 제공하도록 설계된 이니셔티브를 수반합니다. 계획된 전략을 통해 시장 참여자는 조직의 기능적 활동과 일치하여 설정된 목표를 달성할 수 있습니다. 이는 목표를 달성하기 위한 리소스 및 예산 요구 사항을 결정하는 데 있어 회사의 논의 및 의사 결정을 안내하여 운영 효율성을 높입니다.

제약/도전

  • 정형외과 질환의 진단 및 치료 비용이 높다

관절염 및 활액낭염과 같은 만성 정형외과 질환은 MSK 시스템(대부분 뼈 또는 관절)에 영향을 미칩니다. 통증과 기능 장애를 유발하여 일상 생활을 어렵게 만들 수 있습니다. 이러한 상태는 종종 갑작스러운 외상으로 인해 발생하는 어깨 탈구나 뼈 골절과 같은 정형외과적 부상과 다릅니다. 사고나 외상으로 인한 정형외과적 부상과 달리 만성 질환은 일반적으로 진행성으로, 천천히 시작하여 시간이 지남에 따라 악화되거나 발전합니다. 유전적이거나 연령과 관련이 있거나 과도한 사용으로 인해 발생할 수 있습니다.

일부 정형외과적 질환은 치료가 가능하고 일부는 현재 치료할 수 없지만 통증을 줄이고 삶의 질을 개선하기 위해 치료할 수 있습니다. 정확한 진단과 표적 치료는 치료 없이 진행성 질환에서도 문제를 줄이는 데 도움이 될 수 있습니다. 치료 권장 사항은 상태의 유형과 심각도에 따라 다릅니다. 치료는 RICE(휴식, 얼음, 압박 및 거상)에서 대수술까지 다양합니다.

  • MSK 통증 치료에 사용되는 강력한 약물의 증가

MSK 통증은 환자와 의사에게 힘든 상태입니다. 나이, 성별 또는 경제적 지위에 관계없이 많은 성인이 삶의 어느 시점에서 한 번 이상의 MSK 통증을 경험했습니다. 인구의 약 47%가 영향을 받습니다. 그 중 약 39%~45%는 의사의 진찰이 필요한 장기적인 문제입니다. 부적절하게 치료된 MSK 통증은 삶의 질을 저하시키고 심각한 사회경제적 문제를 일으킬 수 있습니다.

다중 모드 진통제와 다학제적 접근 방식은 MSK 통증의 효과적인 치료에서 핵심 요소입니다. 약리학적, 비약리학적 및 개입적 통증 관리 모두 환자의 회복, 웰빙 및 삶의 질을 개선하는 데 중요합니다. 따라서 최근 지침은 약물 사용을 줄이기 위한 예방 전략과 물리적 도구를 권장합니다. 치료에 적절하게 반응하지 않는 환자의 경우, 개입적 통증 관리 및 기타 대체 기술을 적절하게 사용하는 것이 만성 통증 환자의 안전하고 효과적인 치료에 중요합니다.

COVID-19 이후 중동 및 아프리카 근골격계(MSK) 질환 관리 시장에 미치는 영향

팬데믹 동안 MSK 질환 관리 증상은 COVID-19에서 회복된 후에도 여전히 존재하며, 가장 흔한 불만은 피로, 허리 통증, 관절통, 근육통, 요통 및 목 통증입니다. MSK 질환 관리에는 가상 치료 원격 진료 및 디지털 재활 서비스 사용이 증가합니다.

COVID-19 팬데믹 환경에서 원격 진료는 의료 서비스 제공자가 다양한 MSK 질환이 있는 환자에게 재활 서비스를 제공하는 데 실행 가능합니다. 현재 증거에 따르면 일부 MSK 질환의 경우 원격 진료 평가가 신뢰할 수 있고 치료가 효과적일 수 있으며 환자 만족도가 진료실 내 치료보다 좋거나 더 좋을 수 있습니다.

최근 개발 사항

  • 2022년 4월, Airrosti Rehab Center, LLC는 Buoy Health의 혁신적인 헬스케어 마켓플레이스와 파트너십을 맺었습니다. 이 파트너십의 결과로 Buoy의 월 200만 명 이상의 사용자에게 가치 있는 MSK 케어를 제공하고 새로운 MSK 가상 제품을 개발하게 되었습니다.
  • 2022년 3월 DarioHealth Corp.는 Sanofi US와 계약을 체결했습니다. 이 계약은 DarioHealth Corp.의 MSK 질병 관리 디지털 포트폴리오에서 상업적 성장을 가속화하고 DarioHealth Corp. 플랫폼에서 디지털 건강 솔루션을 개발하는 데 중점을 두었습니다.

중동 및 아프리카 근골격계(MSK) 질환 관리 시장 범위

중동 및 아프리카 근골격계(MSK) 질환 관리 시장은 유형, 기술, 통합 유형, 양식, 응용 프로그램, 환자 인구 및 최종 사용자를 기준으로 7개의 주요 세그먼트로 세분화됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내리는 데 도움이 되는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.

유형

  • 디지털 바이오피드백 시스템
  • 근골격계 중심 디지털 앱(MDAS)
  • 솔루션
  • 기타

시장은 유형에 따라 디지털 바이오피드백 시스템, 근골격계 중심 디지털 앱(MDA), 솔루션 및 기타로 구분됩니다.

기술

  • 정밀 모션 기술
  • 컴퓨터 비전 기술
  • 기타 기술

기술은 정밀 모션 기술, 컴퓨터 비전 기술, 기타 기술로 세분화됩니다.

통합 유형

통합 유형을 기준으로 시장은 전화, 태블릿, 컴퓨터 및 기타로 세분화됩니다.

모달리티

  • 가상 치료
  • 대면 치료
  • 맞춤형/개인화된 치료
  • 기타

시장은 방식에 따라 가상 치료, 대면 치료, 맞춤형/개인화 치료 등으로 구분됩니다.

애플리케이션

  • 수술 전 적용
  • 수술 후 적용

시장은 응용 분야별로 수술 전 응용 분야와 수술 후 응용 분야로 구분됩니다.

환자 인구

  • 소아과
  • 성인
  • 노년의학

환자 인구를 기준으로 시장은 소아과, 성인과, 노인과로 구분됩니다.

최종 사용자

  • 병원 및 진료소
  • 요양원
  • 건강 센터
  • 재활 센터
  • 가상/홈 헬스케어 설정
  • 기타

근골격계(MSK) 질병 관리 시장

최종 사용자를 기준으로 시장은 병원 및 진료소, 요양원, 건강 센터, 재활 센터, 가상/가정 의료 환경 및 기타로 세분화됩니다.

중동 및 아프리카 근골격계(MSK) 질병 관리 시장 지역 분석/통찰력

중동 및 아프리카 근골격계(MSK) 질병 관리 시장을 분석하고, 위에 언급된 대로 지역, 유형, 기술, 통합 유형, 양식, 응용 프로그램, 환자 인구 및 최종 사용자별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

이 시장 보고서에서 다루는 국가는 남아프리카공화국, 사우디아라비아, UAE, 이집트, 바레인, 쿠웨이트, 오만, 카타르, 이스라엘, 기타 중동 및 아프리카 국가입니다.

남아프리카공화국은 비용 효율적인 방식으로 첨단 방법을 제공하기 때문에 시장을 지배할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 국내 시장의 개별 시장 영향 요인 및 규정 변경 사항을 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널에 미치는 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 중동 및 아프리카 근골격계(MSK) 질환 관리 시장 점유율 분석

중동 및 아프리카 근골격계(MSK) 질환 관리 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 유럽의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우위가 있습니다. 제공된 위의 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

중동 및 아프리카 근골격계(MSK) 질병 관리 시장에서 활동하는 주요 기업으로는 RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc. 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHIC SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 RESEARCH METHODOLOGY

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 TYPE SEGMENT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET APPLICATION COVERAGE GRID

2.12 THE CATEGORY VS TIME GRID

2.13 SECONDARY SOURCES

2.14 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCE

4.3 KEY STRATEGIC INITIATIVES

4.4 EMERGING TREND ANALYSIS OF DIGITAL REHABILITATION AND DIGITAL PHYSIOTHERAPY IN THE MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET

4.4.1 DIGITAL REHABILITATION

4.4.2 DIGITAL PHYSIOTHERAPY

5 EPIDEMOLOGY

5.1 US

5.2 CANADA

5.3 MEXICO

5.4 GERMANY

5.5 FRANCE

5.6 U.K.

5.7 ITALY

5.8 SPAIN

5.9 RUSSIA

5.1 TURKEY

5.11 BELGIUM

5.12 DENMARK

5.13 NETHERLANDS

5.14 SWITZERLAND

5.15 SWEDEN

5.16 POLAND

5.17 NORWAY

5.18 FINLAND

5.19 CHINA

5.2 JAPAN

5.21 SOUTH KOREA

5.22 INDIA

5.23 AUSTRALIA

5.24 NEW ZEALAND

5.25 SINGAPORE

5.26 THAILAND

5.27 MALAYSIA

5.28 VIETNAM

5.29 TAIWAN

5.3 INDONESIA

5.31 PHILIPPINES

5.32 BRAZIL

5.33 ARGENTINA

5.34 SOUTH AFRICA

5.35 SAUDI ARABIA

5.36 BAHRAIN

5.37 U.A.E

5.38 KUWAIT

5.39 OMAN

5.4 QATAR

5.41 EGYPT

5.42 ISRAEL

6 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 TECHNOLOGICAL ADVANCES IN THE DIAGNOSIS OF MUSCULOSKELETAL DISORDERS (MSDS)

7.1.2 RISING AWARENESS ABOUT MUSCULOSKELETAL DISORDERS (MSDS)

7.1.3 GROWING PREVALENCE OF RHEUMATOID ARTHRITIS (RA)

7.1.4 INCREASING CASES OF BONE FRACTURES

7.2 RESTRAINTS

7.2.1 HIGH COST OF DIAGNOSIS AND TREATMENT OF ORTHOPEDIC DISEASES

7.2.2 RISE IN USE OF HEAVY-DUTY DRUGS IN TREATING MUSCULOSKELETAL (MSK) PAIN

7.3 OPPORTUNITIES

7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.2 USE OF TELEMEDICINE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT

7.3.3 INCREASED USE OF MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT

7.3.4 USE OF HOME HEALTHCARE FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT

7.4 CHALLENGES

7.4.1 CHALLENGES FACED BY PHYSICIANS WHILE TREATING ATHLETES WITH MUSCULOSKELETAL (MSK) DISEASES

7.4.2 STRICT REGULATORY GUIDELINES FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT

8 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 DIGITAL BIOFEEDBACK SYSTEM

8.3 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)

8.3.1 IOS-SYSTEMS

8.3.2 ANDROID-SYSTEMS

8.3.3 OTHER SYSTEMS

8.4 SOLUTIONS

8.4.1 DIRECT SUPPORT

8.4.1.1 MULTIMODAL PAIN THERAPY

8.4.1.2 ONSITE PERSONALIZED THERAPY

8.4.1.3 SOLUTIONS TO REDUCE INJURIES

8.4.1.4 MIND-BODY CONNECTION IMPROVEMENT

8.4.1.5 EARLY PREVENTION AND INTERVENTION

8.4.1.6 PREVENTION, RECOVERY AND EDUCATION

8.4.1.7 PERSONALIZED PAIN RECOVERY

8.4.1.8 SENSOR-GUIDED EXERCISE THERAPY

8.4.1.9 TRAINING OF EDUCATION SKILLS

8.4.1.10 SELF-TRACKING OF PAIN EPISODES

8.4.1.11 RELAXATION TECHNIQUES

8.4.1.12 POST-OPERATIVE PAIN TRACKING

8.4.1.12.1 REAL-TIME MONITORING

8.4.1.12.2 SYMPTOM MANAGEMENT

8.4.1.13 OTHERS

8.4.2 PROGRESS TRACKING

8.4.3 OTHERS

8.5 OTHERS

9 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY

9.1 OVERVIEW

9.2 PRECISION MOTION TECHNOLOGY

9.3 COMPUTER MOTION TECHNOLOGY

9.4 OTHER TECHNOLOGIES

10 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE

10.1 OVERVIEW

10.2 PHONE

10.2.1 DIGITAL BIOFEEDBACK SYSTEM

10.2.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)

10.2.3 THERAPIES

10.2.4 OTHERS

10.3 TABLET

10.3.1 DIGITAL BIOFEEDBACK SYSTEM

10.3.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)

10.3.3 THERAPIES

10.3.4 OTHERS

10.4 COMPUTER

10.4.1 DIGITAL BIOFEEDBACK SYSTEM

10.4.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)

10.4.3 THERAPIES

10.4.4 OTHERS

10.5 OTHERS

11 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY

11.1 OVERVIEW

11.2 VIRTUAL THERAPY

11.2.1 INTERNET BASED

11.2.2 TELEPHONE BASED

11.2.3 MOBILE PHONE APPLICATION

11.2.4 INTERNET BASED WITH TELEPHONE SUPPORT

11.2.5 INTERACTIVE VOICE RESPONSE

11.2.6 VIDEO TELECONFERENCING

11.2.7 MOBILE PHONE APPLICATION WITH TELEPHONE SUPPORT

11.2.8 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT

11.2.9 INTERNET BASED WITH VIDEO CONFERENCING

11.2.10 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT AND INTERNET BASED

11.2.11 OTHERS

11.3 IN-PERSON THERAPY

11.4 CUSTOMIZED/ PERSONALIZED THERAPY

11.5 OTHERS

12 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 PRE-SURGERY APPLICATION

12.2.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY

12.2.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY

12.2.3 LATERAL LUMBAR INTERBODY FUSION SURGERY

12.2.4 INTERNET BASED WITH TELEPHONE SUPPORT

12.2.5 MINIMALLY INVASIVE SPINE SURGERY

12.2.6 MOTION PRESERVING SPINE SURGERY

12.2.7 POSTERIOR CERVICAL FUSION SURGERY

12.2.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY

12.2.9 SACROILIAC JOINT FUSION SURGERY

12.2.10 SCOLIOSIS CORRECTION SURGERY

12.2.11 VERTEBRAL AUGMENTATION SURGERY

12.2.12 FRACTURE FIXATION SURGERY

12.2.13 HIP SURGERY

12.2.13.1 TOTAL HIP REPLACEMENT

12.2.13.2 PARTIAL HIP REPLACEMENT

12.2.13.3 HIP RESURFACING

12.2.13.4 OTHERS

12.2.14 KNEE SURGERY

12.2.14.1 TOTAL KNEE REPLACEMENT

12.2.14.2 PARTIAL KNEE REPLACEMENT

12.2.14.3 MISS FUSION

12.2.14.4 OTHERS

12.3 POST-SURGERY APPLICATION

12.3.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY

12.3.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY

12.3.3 LATERAL LUMBAR INTERBODY FUSION SURGERY

12.3.4 INTERNET BASED WITH TELEPHONE SUPPORT

12.3.5 MINIMALLY INVASIVE SPINE SURGERY

12.3.6 MOTION PRESERVING SPINE SURGERY

12.3.7 POSTERIOR CERVICAL FUSION SURGERY

12.3.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY

12.3.9 SACROILIAC JOINT FUSION SURGERY

12.3.10 SCOLIOSIS CORRECTION SURGERY

12.3.11 VERTEBRAL AUGMENTATION SURGERY

12.3.12 FRACTURE FIXATION SURGERY

12.3.13 HIP SURGERY

12.3.13.1 TOTAL HIP REPLACEMENT

12.3.13.2 PARTIAL HIP REPLACEMENT

12.3.13.3 HIP RESURFACING

12.3.13.4 OTHERS

12.3.14 KNEE SURGERY

12.3.14.1 TOTAL KNEE REPLACEMENT

12.3.14.2 PARTIAL KNEE REPLACEMENT

12.3.14.3 MISS FUSION

12.3.14.4 OTHERS

13 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION

13.1 OVERVIEW

13.2 PEDIATRICS

13.2.1 MALE

13.2.2 FEMALE

13.3 ADULTS

13.3.1 MALE

13.3.2 FEMALE

13.4 GERIATRIC

13.4.1 MALE

13.4.2 FEMALE

14 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS & CLINICS

14.2.1 MULTIPLE

14.2.2 PHYSICAL THERAPIST

14.2.3 NURSE

14.2.4 HEALTH COACH

14.2.5 OTHERS

14.3 NURSING HOMES

14.3.1 MULTIPLE

14.3.2 PHYSICAL THERAPIST

14.3.3 NURSE

14.3.4 HEALTH COACH

14.3.5 OTHERS

14.4 HEALTH CENTERS

14.4.1 MULTIPLE

14.4.2 PHYSICAL THERAPIST

14.4.3 NURSE

14.4.4 HEALTH COACH

14.4.5 OTHERS

14.5 REHABILITATION CENTERS

14.5.1 MULTIPLE

14.5.2 PHYSICAL THERAPIST

14.5.3 NURSE

14.5.4 HEALTH COACH

14.5.5 OTHERS

14.6 VIRTUAL/HOME HEALTH CARE SETTINGS

14.6.1 MULTIPLE

14.6.2 PHYSICAL THERAPIST

14.6.3 NURSE

14.6.4 HEALTH COACH

14.6.5 OTHERS

14.7 OTHERS

15 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION

15.1 MIDDLE EAST AND AFRICA

15.1.1 SOUTH AFRICA

15.1.2 SAUDI ARABIA

15.1.3 BAHRAIN

15.1.4 UAE

15.1.5 KUWAIT

15.1.6 OMAN

15.1.7 QATAR

15.1.8 EGYPT

15.1.9 ISRAEL

15.1.10 REST OF MIDDLE EAST AND AFRICA

16 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 HINGE HEALTH, INC

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 SWORD HEALTH, INC

18.2.1 COMPANY SNAPSHOT

18.2.2 COMPANY SHARE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENT

18.3 OMADA HEALTHA INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 COMPANY SHARE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 KAIA HEALTH

18.4.1 COMPANY SNAPSHOT

18.4.2 COMPANY SHARE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENTS

18.5 WELLNESS COACHES USA, LLC.

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 AIRROSTI REHAB CENTER, LLC

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENTS

18.7 DARIOHEALTH CORP. (2021)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 INCLUDEHEALTH (2021)

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 IMC (2021)

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 KIIO

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 LIMBER HEALTH, INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 MOVEMENT RX (2021)

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 PHZIO (2021)

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 RECOVERYONE

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 SPARTA SCIENCE

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENTS

18.16 SPRITE HEALTH

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENTS

18.17 SIMPLETHERAPY, INC.

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA DIGITAL BIOFEEDBACK SYSTEM IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA PRECISION MOTION TECHNOLOGY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA COMPUTER MOTION TECHNOLOGY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA OTHER TECHNOLOGIES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA IN-PERSON THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA CUSTOMIZED/ PERSONALIZED THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA GERIATRIC IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 59 MIDDLE EAST AND AFRICA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 60 MIDDLE EAST AND AFRICA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 62 MIDDLE EAST AND AFRICA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 63 MIDDLE EAST AND AFRICA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 64 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 65 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 66 MIDDLE EAST AND AFRICA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 67 MIDDLE EAST AND AFRICA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 68 MIDDLE EAST AND AFRICA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 69 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 70 MIDDLE EAST AND AFRICA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 71 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 72 MIDDLE EAST AND AFRICA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 73 MIDDLE EAST AND AFRICA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 74 MIDDLE EAST AND AFRICA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 75 MIDDLE EAST AND AFRICA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 76 MIDDLE EAST AND AFRICA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 77 MIDDLE EAST AND AFRICA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 78 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 79 MIDDLE EAST AND AFRICA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 80 MIDDLE EAST AND AFRICA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 81 MIDDLE EAST AND AFRICA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 82 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 83 MIDDLE EAST AND AFRICA HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 84 MIDDLE EAST AND AFRICA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 85 MIDDLE EAST AND AFRICA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 86 MIDDLE EAST AND AFRICA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 87 MIDDLE EAST AND AFRICA VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 88 SOUTH AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 89 SOUTH AFRICA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 90 SOUTH AFRICA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 91 SOUTH AFRICA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 92 SOUTH AFRICA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 93 SOUTH AFRICA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 94 SOUTH AFRICA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 95 SOUTH AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 96 SOUTH AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 97 SOUTH AFRICA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 98 SOUTH AFRICA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 99 SOUTH AFRICA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 100 SOUTH AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 101 SOUTH AFRICA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 102 SOUTH AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 103 SOUTH AFRICA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 104 SOUTH AFRICA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 105 SOUTH AFRICA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 106 SOUTH AFRICA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 107 SOUTH AFRICA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 SOUTH AFRICA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 109 SOUTH AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 110 SOUTH AFRICA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 111 SOUTH AFRICA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 112 SOUTH AFRICA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 113 SOUTH AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 114 SOUTH AFRICA HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 115 SOUTH AFRICA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 116 SOUTH AFRICA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 117 SOUTH AFRICA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 118 SOUTH AFRICA VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 119 SAUDI ARABIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 120 SAUDI ARABIA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 121 SAUDI ARABIA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 122 SAUDI ARABIA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 123 SAUDI ARABIA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 124 SAUDI ARABIA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 125 SAUDI ARABIA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 126 SAUDI ARABIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 127 SAUDI ARABIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 128 SAUDI ARABIA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 129 SAUDI ARABIA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 130 SAUDI ARABIA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 131 SAUDI ARABIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 132 SAUDI ARABIA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 133 SAUDI ARABIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 134 SAUDI ARABIA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 135 SAUDI ARABIA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 136 SAUDI ARABIA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 137 SAUDI ARABIA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 138 SAUDI ARABIA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 139 SAUDI ARABIA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 140 SAUDI ARABIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 141 SAUDI ARABIA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 142 SAUDI ARABIA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 143 SAUDI ARABIA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 144 SAUDI ARABIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 145 SAUDI ARABIA HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 146 SAUDI ARABIA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 147 SAUDI ARABIA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 148 SAUDI ARABIA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 149 SAUDI ARABIA VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 150 BAHRAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 151 BAHRAIN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 152 BAHRAIN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 153 BAHRAIN MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 154 BAHRAIN SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 155 BAHRAIN DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 156 BAHRAIN POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 157 BAHRAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 158 BAHRAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 159 BAHRAIN PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 160 BAHRAIN TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 161 BAHRAIN COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 162 BAHRAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 163 BAHRAIN VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 164 BAHRAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 165 BAHRAIN PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 166 BAHRAIN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 167 BAHRAIN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 168 BAHRAIN POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 169 BAHRAIN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 170 BAHRAIN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 171 BAHRAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 172 BAHRAIN PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 173 BAHRAIN ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 174 BAHRAIN GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 175 BAHRAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 176 BAHRAIN HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 177 BAHRAIN NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 178 BAHRAIN HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 179 BAHRAIN REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 180 BAHRAIN VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 181 U.A.E MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 182 U.A.E DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 183 U.A.E DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 184 U.A.E MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 185 U.A.E SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 186 U.A.E DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 187 U.A.E POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 188 U.A.E MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 189 U.A.E MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 190 U.A.E PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 191 U.A.E TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 192 U.A.E COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 193 U.A.E MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 194 U.A.E VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 195 U.A.E MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 196 U.A.E PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 197 U.A.E HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 198 U.A.E KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 199 U.A.E POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 200 U.A.E HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 201 U.A.E KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 202 U.A.E MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 203 U.A.E PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 204 U.A.E ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 205 U.A.E GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 206 U.A.E MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 207 U.A.E HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 208 U.A.E NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 209 U.A.E HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 210 U.A.E REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 211 U.A.E VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 212 KUWAIT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 213 KUWAIT DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 214 KUWAIT DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 215 KUWAIT MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 216 KUWAIT SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 217 KUWAIT DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 218 KUWAIT POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 219 KUWAIT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 220 KUWAIT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 221 KUWAIT PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 222 KUWAIT TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 223 KUWAIT COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 224 KUWAIT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 225 KUWAIT VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 226 KUWAIT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 227 KUWAIT PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 228 KUWAIT HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 229 KUWAIT KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 230 KUWAIT POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 231 KUWAIT HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 232 KUWAIT KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 233 KUWAIT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 234 KUWAIT PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 235 KUWAIT ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 236 KUWAIT GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 237 KUWAIT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 238 KUWAIT HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 239 KUWAIT NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 240 KUWAIT HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 241 KUWAIT REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 242 KUWAIT VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 243 OMAN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 244 OMAN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 245 OMAN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 246 OMAN MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 247 OMAN SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 248 OMAN DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 249 OMAN POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 250 OMAN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 251 OMAN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 252 OMAN PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 253 OMAN TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 254 OMAN COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 255 OMAN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 256 OMAN VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 257 OMAN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 258 OMAN PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 259 OMAN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 260 OMAN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 261 OMAN POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 262 OMAN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 263 OMAN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 264 OMAN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 265 OMAN PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 266 OMAN ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 267 OMAN GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 268 OMAN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 269 OMAN HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 270 OMAN NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 271 OMAN HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 272 OMAN REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 273 OMAN VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 274 QATAR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 275 QATAR DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 276 QATAR DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 277 QATAR MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 278 QATAR SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 279 QATAR DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 280 QATAR POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 281 QATAR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 282 QATAR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 283 QATAR PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 284 QATAR TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 285 QATAR COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 286 QATAR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 287 QATAR VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 288 QATAR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 289 QATAR PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 290 QATAR HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 291 QATAR KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 292 QATAR POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 293 QATAR HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 294 QATAR KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 295 QATAR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 296 QATAR PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 297 QATAR ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 298 QATAR GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 299 QATAR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 300 QATAR HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 301 QATAR NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 302 QATAR HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 303 QATAR REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 304 QATAR VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 305 EGYPT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 306 EGYPT DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 307 EGYPT DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 308 EGYPT MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 309 EGYPT SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 310 EGYPT DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 311 EGYPT POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 312 EGYPT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 313 EGYPT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 314 EGYPT PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 315 EGYPT TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 316 EGYPT COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 317 EGYPT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 318 EGYPT VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 319 EGYPT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 320 EGYPT PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 321 EGYPT HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 322 EGYPT KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 323 EGYPT POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 324 EGYPT HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 325 EGYPT KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 326 EGYPT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 327 EGYPT PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 328 EGYPT ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 329 EGYPT GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 330 EGYPT MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 331 EGYPT HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 332 EGYPT NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 333 EGYPT HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 334 EGYPT REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 335 EGYPT VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 336 ISRAEL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 337 ISRAEL DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

TABLE 338 ISRAEL DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)

TABLE 339 ISRAEL MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 340 ISRAEL SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 341 ISRAEL DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)

TABLE 342 ISRAEL POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 343 ISRAEL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 344 ISRAEL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 345 ISRAEL PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 346 ISRAEL TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 347 ISRAEL COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)

TABLE 348 ISRAEL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 349 ISRAEL VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)

TABLE 350 ISRAEL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 351 ISRAEL PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 352 ISRAEL HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 353 ISRAEL KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 354 ISRAEL POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 355 ISRAEL HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 356 ISRAEL KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 357 ISRAEL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 358 ISRAEL PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 359 ISRAEL ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 360 ISRAEL GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)

TABLE 361 ISRAEL MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 362 ISRAEL HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 363 ISRAEL NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 364 ISRAEL HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 365 ISRAEL REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 366 ISRAEL VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)

TABLE 367 REST OF MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 368 REST OF MIDDLE EAST AND AFRICA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)

그림 목록

FIGURE 1 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: GEOGRAPHIC SCOPE

FIGURE 3 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DATA TRIANGULATION

FIGURE 4 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT

FIGURE 5 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BOTTOM-UP APPROACH

FIGURE 6 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: TOP-DOWN APPROACH

FIGURE 7 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: INTERVIEWS BY REGION AND DESIGNATION

FIGURE 8 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: APPLICATION COVERAGE GRID

FIGURE 11 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: THE CATEGORY VS TIME GRID

FIGURE 12 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET SEGMENTATION

FIGURE 13 RISE IN AWARENESS ABOUT MUSCULOSKELETAL (MSK) DISEASES, GROWING PREVALENCE OF RHEUMATOID ARTHRITIS, TECHNOLOGICAL ADVANCEMENTS IN MUSCULOSKELETAL (MSK) DISEASES, AND STRATEGIC INITIATIVES BY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MARKET GROWTH FOR MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN 2023 & 2030

FIGURE 15 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET : EPIDEMIOLOGY

FIGURE 16 PREVALENCE AND INCIDENCE OF RHEUMATOID ARTHRITIS

FIGURE 17 PREVALENCE AND INCIDENCE OF OSTEOARTHRITIS

FIGURE 18 PREVALENCE AND INCIDENCE OF OSTEOPOROSIS

FIGURE 19 PREVALENCE AND INCIDENCE OF PSORIATIC ARTHRITIS

FIGURE 20 PREVALENCE AND INCIDENCE OF ANKYLOSING SPONDYLITIS

FIGURE 21 INCIDENSE OF FIBROMYALGIA

FIGURE 22 PREVALENCE AND INCIDENCE OF TENDINITIS AND CARPEL TUNNEL SYNDROME

FIGURE 23 PREVALENCE AND INCIDENCE OF BONE FRACTURES

FIGURE 24 PREVALENCE AND INCIDENCE OF OSTEOMALACIA AND OSTEOPENIA

FIGURE 25 PREVALENCE AND INCIDENCE OF GOUT

FIGURE 26 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET

FIGURE 27 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2022

FIGURE 28 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 30 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2022

FIGURE 32 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 34 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2022

FIGURE 36 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2023-2030 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, CAGR (2023-2030)

FIGURE 38 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, LIFELINE CURVE

FIGURE 39 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2022

FIGURE 40 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2023-2030 (USD MILLION)

FIGURE 41 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, CAGR (2023-2030)

FIGURE 42 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2022

FIGURE 44 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 45 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 46 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 47 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2022

FIGURE 48 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2023-2030 (USD MILLION)

FIGURE 49 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, CAGR (2023-2030)

FIGURE 50 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, LIFELINE CURVE

FIGURE 51 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2022

FIGURE 52 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 53 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 54 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 55 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022)

FIGURE 56 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022)

FIGURE 57 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 58 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 59 MIDDLE EAST AND AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030)

FIGURE 60 MIDDLE EAST & AFRICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

South Africa is the dominating region of the Middle East and Africa Musculoskeletal (MSK) Disease Management Market.
The Middle East and Africa Musculoskeletal (MSK) Disease Management Market growth rate will be 20.3% by 2030.
The Increasing cases of bone fractures and Technological advances in the diagnosis of musculoskeletal disorders (MSDS) are the growth drivers of the Middle East and Africa Musculoskeletal (MSK) Disease Management Market.
The type, technology, integration type, modality, application, patient population and end-user are the factors on which the Middle East and Africa Musculoskeletal (MSK) Disease Management Market research is based.
The major companies in the Middle East and Africa Musculoskeletal (MSK) Disease Management Market are RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., and Hinge Health, Inc.